Influence of Anti-Tuberculosis Medicines Manufacturer on the Incidence of Adverse Events
Abstract
An analysis of the frequency of adverse events (AEs) associated with anti-tuberculosis drugs (ATDs) reported to the national pharmacovigilance system between 2023 and 2024 was conducted. The focus was on the distribution of AEs by drug manufacturer. The data obtained indicate significant variability in the frequency of AEs depending on the country and manufacturer. The predominance of AE reports associated with certain manufacturers requires further study of the safety profile, bioequivalence, and manufacturing characteristics of these drugs. The causal relationship between drug use and the development of AEs was assessed in accordance with the WHO-UMC classification and was categorized, in most cases, as "possible" or "conditional".
Fields of Study & Subjects
Pharmacovigilance and Adverse Drug Reactions
Tuberculosis Research and Epidemiology
Pharmaceutical Quality and Counterfeiting
Publication details
- Journal / source
- Bulletin of Science and Practice
- Volume
- 12
- Issue
- 3
- Pages
- 273–279
- Publication date
- 12 March 2026
- Language
- RU